ロード中...
Mechanisms of resistance to immune checkpoint inhibitors
Immune checkpoint inhibitors (ICI) targeting CTLA-4 and the PD-1/PD-L1 axis have shown unprecedented clinical activity in several types of cancer and are rapidly transforming the practice of medical oncology. Whereas cytotoxic chemotherapy and small molecule inhibitors (‘targeted therapies’) largely...
保存先:
| 出版年: | Br J Cancer |
|---|---|
| 主要な著者: | , , |
| フォーマット: | Artigo |
| 言語: | Inglês |
| 出版事項: |
Nature Publishing Group
2018
|
| 主題: | |
| オンライン･アクセス: | https://ncbi.nlm.nih.gov/pmc/articles/PMC5765236/ https://ncbi.nlm.nih.gov/pubmed/29319049 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1038/bjc.2017.434 |
| タグ: |
タグ追加
タグなし, このレコードへの初めてのタグを付けませんか!
|